Table 1 Main demographical, clinical and molecular characteristics of the enrolled subjects
| Variable |
SCA2 patients (N = 48) |
Preclinical carriers (N = 25) |
Healthy controls (N = 24) |
|---|---|---|---|
| Gender (female/male) | 19/29 | 16/9 | 15/9 |
| Age (years) |
41.35 ± 9.79 (18–69) |
36.88 ± 9.14 (24–61) |
41.13 ± 11.05 (20–63) |
| Age at onset (years) |
30.06 ± 9.06 (9–60) | NA | NA |
| Disease duration (years) |
11.71 ± 6.08 (3–29) | NA | NA |
| SARA score |
15.81 ± 5.59 (6–30) |
0.76 ± 0.66 (0–2) | 0 |
| Unexpanded CAG repeat (units) |
22.08 ± 0.92) (19–27) |
22.84 ± 1.93 (22–29) |
22.54 ± 1.76 (20–30) |
| Expanded CAG repeat (units) |
39.81 ± 2.92 (35–47) |
35.76 ± 1.90 (32–39) | NA |
